Apomivir® / New Drug Development

Menu

Best Sale

Apomivir® / New Drug Development | Microalgae Based Raw Materials & Finished Products Supplier | FEBICO

Based in Taiwan, Far East Bio-Tec Co., Ltd., since 1976, is an ISO-22000 and HACCP certified Taiwanese manufacturer with more than 4 decades of experiences in producing microalgae based raw materials and finished products, including Chlorella, Spirulina, Chlorella Growth Factor CGF, patented microalgae extract, Nattokinase, probiotics and nutritional supplements. Apart from seeking distributors of FEBICO brand products, we're offering raw materials, finished products, private labeling as well as OEM/ODM services.

FEBICO is the first Naturland/EU Organic Certified Chlorella and Spirulina producer in the world and the first manufacturer receive Organic Chlorella under the USDA-NOP standard certification. In addition, the only “Cracked Cell wall” patent processed chlorella in the world, allowed for 80% absorption.

FEBICO has been offering customers high-quality microalgae based raw materials and finished products, both with advanced technology and 40 years of experience, FEBICO ensures each customer's demands are met.

Apomivir® / New Drug Development

Antiviral drugs for covid 19

Influenza Antiviral Drug
Influenza Antiviral Drug

Far East Bio-Tec Co., Ltd. (FEBICO), founded in 1976, is a top leading brand of microalgae around the world. Far East Microalgae Ind. Co., Ltd. (FEMICO) holds the comprehensive advantages for microalgae cultivation. Our excellent quality systems are HACCP and ISO22000 certified. Microalgae products are organic certified by Naturland, EU and USDA National Organic Program (NOP), as well Halal certified.

We consolidate the strength of research, production, and sales for mass production of microalgae and development of derived biomedical products.

US and TW FDA have approved investigational new drug (IND) application of Apomivir for patients diagnosed with influenza in 2013 and 2014, respectively. FEBICO's current major development of new drug focuses on the treatment of global emerging infectious diseases and hepatitis-related diseases.

Result 1 - 1 of 1

Result 1 - 1 of 1